Samuel Golpanian1, Eduardo A Perez1, Jun Tashiro1, John I Lew2, Juan E Sola1, Anthony R Hogan3. 1. Division of Pediatric Surgery, DeWitt Daughtry Family, Department of Surgery, University of Miami Miller School of Medicine, 1120 N.W. 14th Street, Suite 450J, Miami, FL, 33136, USA. 2. Division of Endocrine Surgery, DeWitt Daughtry Family, Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. 3. Division of Pediatric Surgery, DeWitt Daughtry Family, Department of Surgery, University of Miami Miller School of Medicine, 1120 N.W. 14th Street, Suite 450J, Miami, FL, 33136, USA. ahogan@med.miami.edu.
Abstract
OBJECTIVE: To evaluate outcomes and predictors of survival of pediatric thyroid carcinoma, specifically papillary thyroid carcinoma. METHODS: SEER was searched for surgical pediatric cases (≤20 years old) of papillary thyroid carcinoma diagnosed between 1973 and 2011. Demographics, clinical characteristics, and survival outcomes were analyzed using standard statistical methods. All papillary types, including follicular variant, were included. RESULTS: A total of 2504 cases were identified. Overall incidence was 0.483/100,000 persons per year with a significant annual percent change (APC) in occurrence of 2.07 % from baseline (P < 0.05). Mean age at diagnosis was 16 years and highest incidence was found in white, female patients ages 15-19. Patients with tumor sizes <1 cm more likely received lobectomies/isthmusectomies versus subtotal/total thyroidectomies [OR = 3.03 (2.12, 4.32); P < 0.001]. Patients with tumors ≥1 cm and lymph node-positive statuses [OR = 99.0 (12.5, 783); P < 0.001] more likely underwent subtotal/total thyroidectomy compared to lobectomy/isthmusectomy. Tumors ≥1 cm were more likely lymph node-positive [OR = 39.4 (16.6, 93.7); p < 0.001]. Mortality did not differ between procedures. Mean survival was 38.6 years and higher in those with regional disease. Disease-specific 30-year survival ranged from 99 to 100 %, regardless of tumor size or procedure. Lymph node sampling did not affect survival. CONCLUSIONS: The incidence of pediatric papillary thyroid cancer is increasing. Females have a higher incidence, but similar survival to males. Tumors ≥1 cm were likely to be lymph node-positive. Although tumors ≥1 cm were more likely to be resected by subtotal/total thyroidectomy, survival was high and did not differ based on procedure.
OBJECTIVE: To evaluate outcomes and predictors of survival of pediatric thyroid carcinoma, specifically papillary thyroid carcinoma. METHODS: SEER was searched for surgical pediatric cases (≤20 years old) of papillary thyroid carcinoma diagnosed between 1973 and 2011. Demographics, clinical characteristics, and survival outcomes were analyzed using standard statistical methods. All papillary types, including follicular variant, were included. RESULTS: A total of 2504 cases were identified. Overall incidence was 0.483/100,000 persons per year with a significant annual percent change (APC) in occurrence of 2.07 % from baseline (P < 0.05). Mean age at diagnosis was 16 years and highest incidence was found in white, female patients ages 15-19. Patients with tumor sizes <1 cm more likely received lobectomies/isthmusectomies versus subtotal/total thyroidectomies [OR = 3.03 (2.12, 4.32); P < 0.001]. Patients with tumors ≥1 cm and lymph node-positive statuses [OR = 99.0 (12.5, 783); P < 0.001] more likely underwent subtotal/total thyroidectomy compared to lobectomy/isthmusectomy. Tumors ≥1 cm were more likely lymph node-positive [OR = 39.4 (16.6, 93.7); p < 0.001]. Mortality did not differ between procedures. Mean survival was 38.6 years and higher in those with regional disease. Disease-specific 30-year survival ranged from 99 to 100 %, regardless of tumor size or procedure. Lymph node sampling did not affect survival. CONCLUSIONS: The incidence of pediatric papillary thyroid cancer is increasing. Females have a higher incidence, but similar survival to males. Tumors ≥1 cm were likely to be lymph node-positive. Although tumors ≥1 cm were more likely to be resected by subtotal/total thyroidectomy, survival was high and did not differ based on procedure.
Authors: K D Newman; T Black; G Heller; R G Azizkhan; G W Holcomb; C Sklar; V Vlamis; G M Haase; M P La Quaglia Journal: Ann Surg Date: 1998-04 Impact factor: 12.969
Authors: Bassan J Allan; Bo Wang; James S Davis; Punam P Parikh; Eduardo A Perez; Holly L Neville; Juan E Sola Journal: J Pediatr Surg Date: 2013-10-05 Impact factor: 2.545
Authors: M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier Journal: J Clin Endocrinol Metab Date: 1986-10 Impact factor: 5.958
Authors: M A Tucker; P H Jones; J D Boice; L L Robison; B J Stone; M Stovall; R D Jenkin; J H Lubin; E S Baum; S E Siegel Journal: Cancer Res Date: 1991-06-01 Impact factor: 12.701
Authors: Juan C Gutierrez; Anne C Fischer; Juan E Sola; Eduardo A Perez; Leonidas G Koniaris Journal: Pediatr Surg Int Date: 2007-05-03 Impact factor: 2.003
Authors: Marie-Odile Bernier; Diana R Withrow; Amy Berrington de Gonzalez; Clara J K Lam; Martha S Linet; Cari M Kitahara; Meredith S Shiels Journal: Cancer Date: 2019-04-23 Impact factor: 6.860
Authors: Kwangsoon Kim; Won Woong Kim; Jung Bum Choi; Min Jhi Kim; Cho Rok Lee; Jandee Lee; Sang-Wook Kang; Kee-Hyun Nam; Woong Youn Chung; Jong Ju Jeong Journal: Ann Surg Treat Res Date: 2018-09-28 Impact factor: 1.859
Authors: Chantal A Lebbink; Medard F M van den Broek; Annemiek B G Kwast; Joep P M Derikx; Miranda P Dierselhuis; Schelto Kruijff; Thera P Links; A S Paul van Trotsenburg; Gerlof D Valk; Menno R Vriens; Annemarie A Verrijn Stuart; Hanneke M van Santen; Henrike E Karim-Kos Journal: Cancers (Basel) Date: 2021-10-12 Impact factor: 6.639
Authors: Iván A González; Douglas R Stewart; Kris Ann P Schultz; Amanda P Field; D Ashley Hill; Louis P Dehner Journal: Mod Pathol Date: 2021-10-01 Impact factor: 7.842
Authors: Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze Journal: Endocr Relat Cancer Date: 2022-09-07 Impact factor: 5.900
Authors: Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958
Authors: Julia Ramalho Amalio da Silva Breder; Paulo Alonso Garcia Alves; Mario Lucio Araújo; Barbara Pires; Priscila Valverde; Daniel Alves Bulzico; Fernanda Andrade Accioly; Rossana Corbo; Mario Vaisman; Fernanda Vaisman Journal: Eur Thyroid J Date: 2022-03-08